New technology platforms in the development of vaccines for the future

Glück, Reinhard; Metcalfe, Ian C

doi:10.1016/s0264-410x(02)00513-3

Cited by 61 publications

(21 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the fact that virosomes are already used as vaccine to generate an anti-hepatitis A or Influenza virus immunity (22,23), little is known regarding their ability to develop T cell responses against tumor antigen. Because PDC are thought to be involved in virus detection and antiviral responses, we focused on the interactions between PDC and virosomes, and we asked whether PDC could be a target for inducing antitumoral response.…”

Section: Discussionmentioning

confidence: 99%

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Angel

Chaperot

Molens

et al. 2007

Vaccine

View full text Add to dashboard Cite

Cytotoxic T lymphocytes (CTL) are crucial in viral clearance and tumor growth control. Thus the induction of CTL activity is an important aim in vaccine development. We investigate an innovative delivery system for peptide transfer to the MHC class-I processing pathway of APC with the aim to trigger CTL in the context of an anti-tumoral response. The strategy relies on a novel antigen delivery system termed "chimeric immunopotentiating reconstituted influenza virosomes" (CIRIV) targeting plasmacytoid dendritic cells (PDC). By using virosomes containing encapsulated Melan-A peptide and a PDC line developed in our laboratory, we evaluated the response of Melan-A specific T cells. Virosomes have the capacity to bind PDC and are endocyted within vesicles in the cytosol. This endocytosis is inhibited by neuraminidase, suggesting that it is mediated by sialic acid present on cell surface. Furthermore, PDC loaded with Melan-A virosomes can induce a Melan-A specific T cell activation. Interestingly, they activate T cells with a better efficiency than PDC loaded with a free peptide and when PDC where previously activated by a TLR ligand. These results indicate that virosomes could be a suitable delivery system for tumor peptide in immunotherapy of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Angel

Chaperot

Molens

et al. 2007

Vaccine

View full text Add to dashboard Cite

show abstract

“…One of the virosome-based nanovaccine licensed for influenza is called Inflexal V ® [83]. In these virosomes, two glycoproteins of influenza, including hemagglutinin (HA) and neuraminidase are integrated onto the surface of liposomal structures by covalent or electrostatic interactions [84], increasing the chance of antigen capture and processing by APCs.…”

Section: Polysaccharide and Polyanhydride-based Nanocarriersmentioning

confidence: 99%

Revolutionary impact of nanovaccines on immunotherapy

Shahbazi

Santos

2014

European Journal of Molecular &Amp; Clinical Medicine

View full text Add to dashboard Cite

Over the past few decades, public health has been immensely improved by preventing various types of diseases using vaccination, a method implying attenuated, killed or part of a microorganism to activate the immune system against it. Recently, nanovaccines have attracted a lot of attention as a new approach for enhancing the immune responses against immunogenic molecules. A wide variety 2 of nanomaterials are reported as proper candidates for nano-vaccination. Currently, the focus of nanovaccines researches are developing new formulations that trigger strong anti-cancer responses by presenting tumor antigens either directly to T immune cells or indirectly to antigen-presenting cells, holding great promise for safe, non-invasive, and cost-effective therapy of cancer. This review focuses on the critical aspects in the design of biomaterial based nanovaccines and reviews the state of the art of the formulations in clinical development and those currently marketed. Focal points:• BedsideUnderstanding the complex potential of the immune system to prevent and treat various diseases such as cancer, will contribute to the scientific advance in the development of new therapeutic strategies and will allow for the discovery of alternative treatments for deadly diseases. • BenchsideMany of the immunostimulative pathways involved in the suppression of cancer tumor growth have been identified and additional research is still needed to recognize the molecular mechanisms of the immunotherapeutic strategies. • IndustryThe discovery of new non-toxic immunotherapeutic compounds may pave the way towards developing new cancer tumor therapeutic approaches. A major effort in the identification of preventing approaches is also needed to develop preventive nanoformulations for healthy people who are at the risk of cancer. • CommunityThe treatment of cancer by cheap, efficient and as less invasive as possible methodologies will have a great impact on the quality of life of the patients. • GovernmentsSince the development of anticancer nanoformulations needs extensive support from the authorities for success in clinical translation, the financial investments of the governments is necessary to translate the research in the lab to the bedside. The governmental support can also increase the years of healthy life of the patients and minimize the associated costs overtime.

show abstract

“…Gene-and protein-based microarrays can be used to detect pathogen signals, to monitor resistance to anti-infective agents, to characterize host gene responses to recent infections, and to facilitate the development of new drugs and vaccines 93 . Basic and applied research together have provided promising new vaccine platforms, such as recombinant proteins, immunogenic peptides, naked DNA vaccines, viral vectors of extraneous genes encoding immunogenic proteins (including chimaeras), replicons and pseudovirions 94 . Many novel vaccine candidates are now being developed against EIs such as HIV, Ebola virus, West Nile virus, dengue, the SARS coronavirus, tuberculosis and malaria.…”

Section: Meeting the Challenge Of Emerging Infectionsmentioning

confidence: 99%

Erratum: The challenge of emerging and re-emerging infectious diseases

Morens¹,

Folkers²

2010

Nature

View full text Add to dashboard Cite

Infectious diseases have for centuries ranked with wars and famine as major challenges to human progress and survival. They remain among the leading causes of death and disability worldwide. Against a constant background of established infections, epidemics of new and old infectious diseases periodically emerge, greatly magnifying the global burden of infections. Studies of these emerging infections reveal the evolutionary properties of pathogenic microorganisms and the dynamic relationships between microorganisms, their hosts and the environment.

show abstract

New technology platforms in the development of vaccines for the future

Cited by 61 publications

References 40 publications

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells

Revolutionary impact of nanovaccines on immunotherapy

Erratum: The challenge of emerging and re-emerging infectious diseases

Contact Info

Product

Resources

About